Resumen
Purpose: We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. Methods: This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction. All subjects underwent imaging of the chest/abdomen/pelvis to establish a post-surgical baseline prior to the initiation of chemotherapy. Information collected on trial was utilized to compare surgeon's operative assessment of RD, to pre-treatment imaging. Results: Of 1873 enrolled patients, surgical outcome was described as optimal (RD ≤ 1 cm) in 639 subjects. Twelve patients were excluded as they did not have a baseline, pretreatment imaging, leaving 627 participants for analysis. The average interval from surgery to baseline scan was 26 days (range: 1–109). In 251 cases (40%), the post-operative scan was discordant with surgeon assessment, demonstrating RD > 1 cm in size. RD > 1 cm was most commonly identified in the right upper quadrant (28.4%), retroperitoneal para-aortic lymph nodes (RD > 1.5 cm; 28.2%) and the left upper quadrant (10.7%). Patients with RD > 1 cm on pre-treatment CT (discordant) exhibited a significantly greater risk of disease progression (HR 1.30; 95% CI 1.08–1.56; p = 0.0059). Conclusions: Among patients reported to have undergone optimal cytoreduction, 40% were found to have lesions >1 cm on postoperative, pretreatment imaging. Although inflammatory changes and/or rapid tumor regrowth could account for the discordance, the impact on PFS and distribution of RD may suggest underestimation by the operating surgeon.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 525-530 |
| Número de páginas | 6 |
| Publicación | Gynecologic Oncology |
| Volumen | 149 |
| N.º | 3 |
| DOI | |
| Estado | Published - jun 2018 |
Nota bibliográfica
Publisher Copyright:© 2018
Financiación
This study was supported by National Cancer Institute grants NRG Oncology SDMC grant U10 CA180822 and the NRG Oncology Operations grant U10CA 180868 . The clinical trial upon which this manuscript is based was sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), under the Collaborative Research and Development Agreement (CRADA) for bevacizumab between NCI and Genentech, Inc. This study was supported by National Cancer Institute grants NRG Oncology SDMC grant U10 CA180822 and the NRG Oncology Operations grant U10CA 180868. The clinical trial upon which this manuscript is based was sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), under the Collaborative Research and Development Agreement (CRADA) for bevacizumab between NCI and Genentech, Inc.
| Financiadores | Número del financiador |
|---|---|
| Cancer Therapy Evaluation Program | |
| NRG Oncology Operations | |
| NRG Oncology SDMC | |
| National Childhood Cancer Registry – National Cancer Institute | U10CA 180868, U10 CA180822, U10CA037517 |
| National Childhood Cancer Registry – National Cancer Institute | |
| Genentech Incorporated | |
| National Fisheries Research and Development Institute (NFRDI) | CRADA |
| National Fisheries Research and Development Institute (NFRDI) |
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology